Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study (NCT02740634) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
United States60 participantsStarted 2016-05
Plain-language summary
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
Who can participate
Age range21 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Over the age of 21
* Must have an informant who will be able to provide independent evaluation of functioning
* English is primary language
* All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
* All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
* All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain
Exclusion Criteria:
* If you have had a stroke or tumor that could explain your symptoms
* Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
* Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
* Subjects will be excluded if they have poor vision (20/400)
* Women that are pregnant or post-partum and breast-feeding will be excluded
* Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic cond…
What they're measuring
1
Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
Timeframe: 5 years
2
Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).